A study had shown that the recurrence rate of the same irAEs resulting in discontinuation of ICI treatment in cancer patients who rechallenged the same ICI was 28.6% (anti-PD-1 or anti-PD-L1 monotherapy), 47.4% (anti-CTLA-4 monotherapy), and 43.5% (combination therapy), respectively [66]. The gene discussed is PDCD1; the disease is cancer.